SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as the community discusses the stock's volatility and potential for a short squeeze. Recent news of a contract win is fueling optimism, though a proposed increase in authorized shares has sparked concerns about dilution. Bullish investors are focused on the company's long-term prospects in the drone and counter-UAS technology sectors.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to its GPU-accelerated quantum algorithm simulation and compatibility with NVIDIA's CUDA-Q, sparking discussions about accelerated quantum computing. Investors are speculating on potential partnerships, future growth, and the company's positioning within the quantum computing sector. Community members are also discussing the potential for a short squeeze.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending following positive data from Roche on a similar breast cancer drug, sparking significant intraday volatility and a surge in price. The community is actively debating whether this jump is justified, discussing potential short squeezes, imminent offerings, and the overall valuation of OLMA in light of the news. Some traders are wary of a potential pullback, while others see further upside based on pipeline potential and analyst upgrades.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition, with Paramount Skydance reportedly preparing a $71 billion bid. The community is discussing the likelihood of a bidding war, potential involvement of other major players like Netflix and Comcast, and the possible impact of regulatory hurdles. Community talking points include speculation around a potential overbid. 

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

MCRB is trending amid ongoing speculation of a potential acquisition by Nestl, with community chatter focusing on the timing and likelihood of a deal. Recent workforce reductions and executive departures have fueled rumors, while some traders point to technical indicators suggesting a potential short squeeze. Uncertainty persists around the company's strategic direction and whether it will pursue a partnership instead of a buyout.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet (STRK) is trending as analysts highlight its breakout from a rounding-bottom pattern and potential Wave 3 run, with some targeting $0.50. Community excitement is fueled by growing BTCFi integration, increased staking volume, and the network's focus on quantum-resistant technology. Discussions also focus on Starknet's strong performance compared to other Layer-2 solutions and its growing ecosystem.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as anticipation builds for presentations at the upcoming AASLD Liver Meeting, with the community focused on new biomarker data and potential partnerships. Discussion is centered on Belapectin's potential synergy with GLP-1 drugs and speculation about a possible short squeeze, given the high short interest. Investors are closely watching for any indications of a potential buyout before the year's end.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending amid discussions of a potential LTV contract award and recent insider buying, fueling speculation about the company's future prospects in lunar exploration. The community is weighing the significance of upcoming catalysts like the IM3 mission and the potential for a Saudi investment, while also debating the impact of market conditions and short selling on the stock's performance. Bullish sentiment is building with many highlighting the company's long-term potential in the space sector following recent acquisitions.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to positive clinical trial results for its drug Tradipitant in reducing nausea and vomiting induced by the popular weight loss drug Wegovy. The community is buzzing about the potential buyout scenarios and higher valuation, while some express concerns over management's past decisions and spending habits. Bullish sentiment prevails with many expecting the company's market value to increase significantly.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following FDA approval of their first drug, REDEMPLO, for a rare genetic disorder, Familial Chylomicronemia Syndrome (FCS). The community is excited about the potential for revenue generation and the validation of their RNAi platform, with some anticipating a valuation reset and potential for significant upside. Discussions also highlight the drug's competitive advantages, pipeline, and possible expansion into broader indications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BNY Mellon Municipal Bond Closed-End Funds Declare Distributions

BNY Mellon Investment Adviser, Inc. announced today that BNY Mellon Municipal Income, Inc., BNY Mellon Strategic Municipal Bond Fund, Inc. and BNY Mellon Strategic Municipals, Inc. (each, a 'Fund...

Special Opportunities Fund Announces Results of Annual Meeting of Stockholders of BNY Mellon Municipal Income

Special Opportunities Fund, Inc. (the Fund) (NYSE: SPE) announced today that, at the annual meeting of stockholders of BNY Mellon Municipal Income (NYSE: DMF) held on June 12, 2024, (1) Phillip...

BNY Mellon Municipal Income Fund, Inc. (NYSE: DMF) Declares Distribution

On May 8, 2024, BNY Mellon Municipal Income Fund, Inc. (NYSE: DMF) today declared a distribution of $0.019 per share of common stock, payable on June 28, 2024 to shareholders of record at the close...

BNY Mellon Municipal Income Fund, Inc. (NYSE: DMF) today declared a distribution of $0.019 per share of common stock, payable on June 28, 2024 to shareholders of record at the close of business on...

BNY Mellon Municipal Income, Inc. engages in the provision of access to equity, fixed income and money market mutual funds, separately managed accounts, retirement and cash management strategies, and asset allocation solutions. The company was founded in 1947 and is headquartered in New York, NY.

DMF
Dreyfus Municipal Income Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DMF News

DMFDreyfus Municipal Income Inc.